Magneto Thrombectomy Solutions

Company Overview

Snapshot

Founded in May 2016, Magneto Thrombectomy Solutions operates with 1–10 employees. The company has raised a total of $1.85M across 5 funding rounds from 1 investor. In March 2025, the company secured a grant from the European Union’s EIC Fund.

Business overview

Magneto Thrombectomy Solutions is dedicated to developing innovative solutions for the removal of blood clots within the vascular system. The company's core technology utilizes electric fields to create an attraction with target clots, enabling removal without damaging the vessel's endoluminal surface and reducing the risk of distal embolization. Their eTrieve™ PE kit, custom-designed for pulmonary arteries, employs a large bore aspiration catheter alongside proprietary electric attachment technology to remove both proximal and distal emboli. Magneto Thrombectomy Solutions operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, serving the healthcare provider market.

Strategic signal

In May 2022, Magneto Thrombectomy Solutions announced successful first-in-human (FIH) study results for its eTrieve™ PE Kit in treating pulmonary embolism. This milestone is significant as it demonstrates the safety and efficacy of their proprietary electric attachment technology in a clinical setting, validating its potential to address a critical medical need. The positive outcomes, including a reduction in RV/LV ratio and alleviation of PE symptoms, signal strong clinical progress and de-risking for investors, suggesting a clear path towards broader market adoption and further development in thrombectomy solutions.

Company Intelligence Q&A

What is Magneto Thrombectomy Solutions' primary focus?

Magneto Thrombectomy Solutions is focused on developing innovative thrombectomy solutions for the removal of blood clots in the vascular system, utilizing electric fields to create an attraction with the target clot.

When was Magneto Thrombectomy Solutions founded?

Magneto Thrombectomy Solutions was founded in May 2016.

What was a significant clinical milestone for the company?

In May 2022, Magneto Thrombectomy Solutions announced successful first-in-human results for the treatment of pulmonary embolism (PE) using its eTrieve™ PE kit, demonstrating safety and efficacy.

Which investor has participated in Magneto Thrombectomy Solutions' funding rounds?

Peregrine Ventures has participated in multiple funding rounds for Magneto Thrombectomy Solutions, including rounds in January 2023, March 2024, and October 2024.

Has Magneto Thrombectomy Solutions received any grants?

Yes, in March 2025, Magneto Thrombectomy Solutions secured a grant from the European Union’s EIC Fund.